You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Emerging Practice Strategies for PI3K Inhibitors in Relapsed/Refractory Follicular Lymphoma

  • Authors: Loretta Nastoupil, MD; Martin Dreyling, MD
  • CME / ABIM MOC Released: 6/7/2021
  • Valid for credit through: 6/7/2022
Start Activity

Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists.

The goal of this activity is to increase clinicians' awareness of emerging treatment strategies for using phosphatidylinositol-3-kinase (PI3K) inhibitors in relapsed/refractory (R/R) follicular lymphoma (FL).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Emerging strategies for the use of PI3K inhibitors in R/R FL


As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


  • Loretta Nastoupil, MD

    Associate Professor
    Department of Lymphoma/Myeloma
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States


    Disclosure: Loretta Nastoupil, MD, has the following relevant financial relationships:
    Advisor or consultant for: ADC Therapeutics; Bayer; Bristol Myers Squibb/Celgene; Genentech; Gilead/Kite; Janssen; Novartis; TG Therapeutics
    Grants for clinical research from: Bristol Myers Squibb/Celgene; Genentech; Janssen; TG Therapeutics

  • Martin Dreyling, MD

    Professor of Medicine
    Department of Medicine III
    Ludwig Maximilian University Hospital
    Munich, Germany


    Disclosure: Martin Dreyling, MD, has the following relevant financial relationships:
    Advisor or consultant for: AstraZeneca; Bayer; Beigene; Celgene; Gilead; Janssen; Novartis; Roche
    Speaker or a member of a speakers bureau for: Bayer; Celgene; Gilead; Janssen; Roche
    Grants for clinical research from: AbbVie; Bayer; Celgene; Janssen; Roche


  • Megan Whitney, DMD

    Medical Education Director, Medscape, LLC


    Disclosure: Megan Whitney, DMD, has disclosed no relevant financial relationships.

CME Reviewer

  • Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Hazel Dennison, DNP, RN, FNP-BC, CPHQ, CNE, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for Kite / Gilead

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Emerging Practice Strategies for PI3K Inhibitors in Relapsed/Refractory Follicular Lymphoma

Authors: Loretta Nastoupil, MD; Martin Dreyling, MDFaculty and Disclosures

CME / ABIM MOC Released: 6/7/2021

Valid for credit through: 6/7/2022




  • Print